4D Molecular Therapeutics
FDMT
140 hedge funds and large institutions have $630M invested in 4D Molecular Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 57 increasing their positions, 44 reducing their positions, and 25 closing their positions.
38% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $1.21M
30% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 44
1.15% more ownership
Funds ownership: 110.9% → 112.06% (+1.2%)
2% less funds holding
Funds holding: 143 → 140 (-3)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
48% less capital invested
Capital invested by funds: $1.2B → $630M (-$574M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$57.4M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$18M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$14.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.3M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$8.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$61.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$15M |
| 4 |
Goldman Sachs
New York
|
-$9.01M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.61M |
FDMT Hedge Fund Activity: Q3 2024 in Review
140 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2024, worth a combined $630M — down 48% from $1.2B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of FDMT and 22 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 57 added.
The largest buyer was BVF Inc, adding an estimated $57.4M. The largest seller was Viking Global Investors, exiting entirely with an estimated $61.6M sold.
- 140 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2024, down from 143 in Q2 2024.
- Funds reported $630M of 4D Molecular Therapeutics stock for Q3 2024, down 48% quarter-over-quarter.
- 22 funds opened new 4D Molecular Therapeutics positions in Q3 2024 and 25 closed out, a net change of -3 holders.
- The largest 4D Molecular Therapeutics buyer in Q3 2024 was BVF Inc, an estimated $57.4M added.
- The largest 4D Molecular Therapeutics seller in Q3 2024 was Viking Global Investors, an estimated $61.6M sold.
Based on aggregated 13F filings for Q3 2024.